FIELD: pharmaceutics.
SUBSTANCE: invention relates to a conjugate of formula (I) for treating tumors expressing PSMA, including a PSMA ligand with a linker and an anti-tumor preparation MMAE, a composition for preparing a lyophilizate based thereon, dosage form for therapy and inhibition of growth of prostate tumor expressing PSMA, obtained by lyophilisation of said composition, solution for infusions or injections containing such a dosage form, reduced with a solvent containing ethyl alcohol 95 % and polysorbate 80 at weight ratio (30–60):(70–40), respectively.
EFFECT: technical result of claimed group of inventions is high affinity and selectivity of action of disclosed conjugates in relation to cells expressing PSMA.
12 cl, 15 dwg, 27 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONJUGATE OF A FLUORESCENT DYE WITH A PEPTIDE SUBSTANCE WHICH CONTAINS A PSMA-BINDING LIGAND BASED ON A UREA DERIVATIVE FOR VISUALIZING CELLS EXPRESSING PSMA, A METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2019 |
|
RU2713151C1 |
| COMPOUND FOR DIAGNOSING TUMOURS EXPRESSING PSMA AND COMPOSITION BASED THEREON | 2019 |
|
RU2730507C1 |
| PEPTIDE AGENT COMPRISING A PSMA-BINDING LIGAND BASED ON A UREA DERIVATIVE, A METHOD FOR PRODUCTION THEREOF AND USE THEREOF FOR PREPARING A CONJUGATE WITH A DRUG AND DIAGNOSTIC AGENT | 2018 |
|
RU2697519C1 |
| METHOD OF OBTAINING PSMA-TARGET COMPOUND COMPLEX BASED ON UREA Lu-PS-161 AND COMPLEX | 2023 |
|
RU2808636C1 |
| LYOPHILISATE BASED ON PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS FOR PREPARING A RADIOPHARMACEUTICAL COMPOSITION IN FORM OF SOLUTION FOR INJECTIONS FOR TREATING PROSTATE CANCER, RADIOPHARMACEUTICAL COMPOSITION BASED ON IT FOR TREATING PROSTATE CANCER AND METHOD FOR PREPARING RADIOPHARMACEUTICAL COMPOSITION | 2023 |
|
RU2817970C1 |
| MONOMETHYLVALINE COMPOUNDS CAPABLE OF FORMING CONJUGATES WITH LIGANDS | 2004 |
|
RU2448117C2 |
| PEPTIDE COMPOUND CAPABLE OF BINDING WITH PSMA, METHOD FOR PRODUCTION AND USE THEREOF | 2021 |
|
RU2823164C2 |
| COMPLEX OF UREA DERIVATIVE WITH Tc RADIONUCLIDE LABEL FOR DIAGNOSIS OF TUMORS EXPRESSING PROSTATE-SPECIFIC MEMBRANE ANTIGEN, AND METHOD FOR PRODUCTION THEREOF | 2023 |
|
RU2825402C1 |
| PSMA-TARGET COMPOUND AND ITS COMPLEX WITH RADIONUCLIDES FOR THERANOSTICS OF TUMOR EXPRESSING PSMA | 2022 |
|
RU2803734C1 |
| PHOTOSENSITIZER FOR PHOTODYNAMIC THERAPY OF PROSTATE CANCER AND METHOD FR MANUFACTURING THEREOF | 2018 |
|
RU2670087C1 |
